Compare DAKT & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | VTYX |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 713.6M |
| IPO Year | 1994 | 2021 |
| Metric | DAKT | VTYX |
|---|---|---|
| Price | $19.20 | $8.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $26.00 | $14.60 |
| AVG Volume (30 Days) | 415.5K | ★ 1.7M |
| Earning Date | 12-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $770,283,000.00 | N/A |
| Revenue This Year | $12.94 | N/A |
| Revenue Next Year | $7.16 | N/A |
| P/E Ratio | $128.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.24 | $0.78 |
| 52 Week High | $24.38 | $10.55 |
| Indicator | DAKT | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 52.50 | 47.82 |
| Support Level | $18.58 | $7.94 |
| Resistance Level | $21.28 | $8.52 |
| Average True Range (ATR) | 0.88 | 0.58 |
| MACD | 0.17 | -0.22 |
| Stochastic Oscillator | 50.45 | 22.39 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.